🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSUSTAIN-6 to SELECT — what worked for you? Page 3

SUSTAIN-6 to SELECT — what worked for you?

fiona_VT Sat, Aug 16, 2025 at 4:04 PM 38 replies 1,492 viewsPage 3 of 8
Dr.SportsMedIN
Senior Member
1,456
6,789
Feb 2024
Indianapolis, IN
Aug 22, 2025 at 4:49 AM#11
EndoResFellow said:
The mechanism that matters here is not stomach emptying, it is central.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

43 16lucas_SP_BR, lisa_labSD, adam_van and 40 others
Reply Quote Save Share Report
AmyNC_wife
Member
634
2,890
Jun 2024
North Carolina
Aug 24, 2025 at 3:12 PM#12
MounjBrad said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Thank you for spelling out the reasoning rather than just the conclusion.

44 17julia.endo, JessicaM_2024, TomFromTexas and 41 others
Reply Quote Save Share Report
lisa_labSD
Member
278
1,234
Oct 2024
San Diego, CA
Aug 27, 2025 at 1:34 AM#13
EndoResFellow said:
The mechanism that matters here is not stomach emptying, it is central.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

That is the short version; the long version is somebody else's post.

45 18Dr.PulmRoch, maya_sedona, stefan_berlin and 42 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
DoseLogDan
Member
201
567
Feb 2025
Montana
Aug 29, 2025 at 11:54 AM#14
fiona_VT said:
My reason for being on this is cardiovascular rather than cosmetic, which puts me in a small minority in most of these threads.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
46 19sophie_paris, mel_PDX, Dr.AddMedPHL and 43 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Aug 31, 2025 at 10:13 PM#15

Moderator note: a couple of off-topic posts removed. Report rather than reply if it drifts again.

47 20PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph and 44 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register